Infant Bacterial Therapeutics announced that the company had reached a key milestone in the development of IBP-9414, after having recruited 600 premature infants to The Connection Study. The Data Monitoring Committee (DMC) has completed its pre-scheduled safety analysis without any concerns. At the same time a futility analysis was performed.

Based on DMC recommendations and futility outcome, the company is continuing the recruitment to the study as planned. The phase III study, which started July 2019, is open for recruitment of prematurely born infants between 500g and 1,000g across the US, Bulgaria, France, Hungary, Israel, Poland, Romania, Serbia, Spain, and the UK.